<SEC-DOCUMENT>0001193125-25-067908.txt : 20250331
<SEC-HEADER>0001193125-25-067908.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331084025
ACCESSION NUMBER:		0001193125-25-067908
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284606
		FILM NUMBER:		25789107

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d939122d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-284606 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
February&nbsp;5, 2025) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>1,373,333 American Depositary Shares representing 137,333,300 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g939122g0317152830568.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February&nbsp;5, 2025 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-284606),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on March 31, 2025 (the &#147;March 31, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have attached the
March 31, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the
information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On March 28, 2025, the last reported sale price of
the ADSs on Nasdaq was $0.8801 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk
Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently
filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is March 31, 2025 </B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of March, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 31, 2025, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled &#147;Kazia Therapeutics
Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil&#148;. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr.&nbsp;John
Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT
STYLE="white-space:nowrap">333-281937).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated March 31, 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)<B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 31 March 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g939120dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31 March 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kazia
Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Kazia to receive USD $1&nbsp;million
from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, March 31, 2025 &#150; Kazia
Therapeutics Limited (NASDAQ: KZIA) (&#147;Kazia&#148; or &#147;the Company&#148;), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD $1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantrixil from Kazia Therapeutics. Having decided not to
pursue development of Cantrixil in ovarian cancer, as originally anticipated under the license, Vivesto is currently exploring Cantrixil preclinically for the treatment of hematological cancers. Cantrixil, a legacy molecule in the Kazia pipeline, is
a product candidate consisting of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TRXE-002-01,</FONT></FONT> encapsulated in
&#945;-cyclodextrin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to enter into this agreement with Vivesto, which provides a source of
<FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding that will help advance our proprietary, clinical-stage pipeline,&#148; said John Friend, M.D., Chief Executive Officer of Kazia Therapeutics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor and Media Contacts: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alex Star, Managing
Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Advisors LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-201-786-8795.</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astarr@lifesciadvisors.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib,
an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in
this disease. A completed Phase 2/3 study in glioblastoma <FONT STYLE="white-space:nowrap">(GBM-Agile)</FONT> was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard
approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was
granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases
harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for
atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active
against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For
more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g939120dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials,
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, the potential benefits and costs to Kazia of the sale of all of its
intellectual property and trademarks rights to Cantrixil to Vivesto, timing for any regulatory submissions or discussions with regulatory agencies, and the potential market opportunity for paxalisib. Such statements are based on Kazia&#146;s current
expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking
statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties
are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as
of the date of this announcement. This announcement was authorized for release by Dr John Friend, CEO </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g939120dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g939120dsp4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-(54)(04T@
M5$E705))    !9 #  (    4   0J) $  (    4   0O)*1  (    #-#4
M )*2  (    #-#4  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C4Z,#,Z,3<@,38Z,3@Z,C8 ,C R-3HP
M,SHQ-R Q-CHQ.#HR-@   %, 2 !5 $( 2 !! $T ( !4 $D 5P!! %( 20
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1"  X +@# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MN'0-QGTS7T?2J1M(=.5T>*_$?X<^&= TC4?$%Q>WYNKB5C##YB;6E<DX^[G
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g939122g0317152830568.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g939122g0317152830568.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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M>X,F**?4WGT+.A6<_C[QNS:A< *Q,L@SSM'\*U[]:VT-I:QV]NBQQ1J%15'
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0M%)10,6BDHH 6BDHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
